Summary

B-ALL is a cancer of the white blood cells. White blood cells are made in the bone marrow, and these cells aid in fighting infections. White blood cells can mature into specialized cells with unique functions. With B-ALL, the white blood cells become abnormal as they mature. These abnormal white blood cells are called blasts. As the blasts grow and divide, they can displace normal, healthy cells. The blasts spread into the bloodstream. Blasts can also spread to the brain, spinal cord, testes, and other places in the body.

Description

Official Title:  A Phase 2 Study of Blinatumomab (NSC# 765986) in Combination With Nivolumab (NSC# 748726), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >/= 1 to < 31 Years Old With First Relapse

Principal Investigator

Mohamad Badawi

Study Coordinator

Lisa Luikart

Faculty Contact

Mohamad Badawi

Research Contact

Lisa Luikart - lisa.luikart@vandaliahealth.org

Sex

All

Age

1-30 years

NCT Number

NCT04546399

IRB Number

26-1394

Phase(s)

Phase II